| Company | Date | Position | Consensus ⓘ | Price Target ⓘ | 1-Yr Return | vs S&P 500 ⓘ |
|---|---|---|---|---|---|---|
|
GB:0MGB
Genmab A/S
|
Aug 07, 2026 | BUY |
Buy
+0.2% avg upside
23 analysts
|
$2700.00
35.08% Upside
|
· | · |
|
GB:0QW0
arGEN X
|
Aug 06, 2026 | HOLD |
Strong Buy
-19.2% avg upside
24 analysts
|
— | · | · |
|
ARGX
Argenx Se
|
Aug 06, 2026 | HOLD |
Strong Buy
-9.3% avg upside
47 analysts
|
$960.00
10.90% Upside
|
+0.5% | · |
|
GB:0NZT
UCB SA
|
Aug 04, 2026 | BUY |
Buy
-1.4% avg upside
19 analysts
|
$310.00
36.94% Upside
|
· | · |
|
FR:IPN
Ipsen
|
Aug 03, 2026 | HOLD |
Hold
-20.6% avg upside
17 analysts
|
$170.00
5.18% Upside
|
+3.2% | · |
|
ZLDPF
Zealand Pharma
|
May 08, 2026 | BUY |
Buy
+61.0% avg upside
11 analysts
|
$112.61
123.01% Upside
|
-11.2% | · |
|
NL:LKFT
Galapagos
|
Apr 01, 2026 | HOLD |
Sell
+114.7% avg upside
16 analysts
|
$30.00
28.48% Upside
|
-12.2% | · |
|
CH:BIOV
BioVersys AG
|
Dec 11, 2025 | BUY |
Strong Buy
+60.0% avg upside
2 analysts
|
$48.00
74.60% Upside
|
+10.4% | · |
|
CH:LONN
Lonza Group Ltd
|
Feb 06, 2023 | BUY |
Strong Buy
+13.0% avg upside
21 analysts
|
$605.00
5.63% Upside
|
-20.6% | · |
|
DE:MDG1
Medigene
|
Aug 04, 2022 | BUY |
Buy
+79900.0% avg upside
2 analysts
|
$8.00
79900.01% Upside
|
· | · |
|
GB:0FWY
SalMar ASA
|
May 26, 2020 | HOLD |
Sell
+0.9% avg upside
5 analysts
|
$450.00
12.37% Downside
|
+49.1% | · |
|
GB:0OAW
Mowi ASA
|
Feb 17, 2020 | BUY |
Strong Buy
+16.3% avg upside
6 analysts
|
$255.00
27.59% Upside
|
-13.7% | · |
|
NL:CRBN
Corbion NV
|
Nov 01, 2019 | BUY |
Strong Buy
+58.1% avg upside
7 analysts
|
$31.00
54.46% Upside
|
+56.5% | · |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.